Prevalence of Psoriatic Arthritis in Patients with Moderate-to-Severe Psoriasis in the Era of Biologics and Small Molecule Therapies.
Loading...
Identifiers
Publication date
Authors
Vergara Dangond, Cristina
Cobo Ibáñez, María Tatiana
Valverde Garrido, Ricardo
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
SDG
Metrics
Abstract
This study aims to estimate the prevalence of psoriatic arthritis (PsA) and associated factors in patients with moderate-to-severe psoriasis. The study develops a retrospective, single-center study of a cohort of psoriasis patients in standard follow-up in a dermatology department from July 2008 to January 2024. Patients ≥18 years with moderate-to-severe psoriasis were included and classified into three groups according to the treatment received: group 1, biologics or small molecules with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs); group 2, only csDMARDS; and group 3, non-pharmacological treatments. Demographic and clinical variables were collected.
Description
Keywords
Bibliographic reference
Vergara-Dangond, C., Cobo-Ibáñez, T., Cueva-Nájera, G., Valverde-Garrido, R., García-Yubero, C., Trives-Folguera, L., Paredes-Romero, B., Esteban-Vázquez, A. V., Romero-Bogado, L., De La Cámara-Fernández, I., Steiner, M., Richi-Alberti, P., Acosta-Alfaro, A. V., Prats, I., & Muñoz-Fernández, S. (2025). Prevalence of psoriatic arthritis in patients with moderate-to-severe psoriasis in the era of biologics and small molecule therapies. Journal of Clinical Medicine, 14(23), 8359. https://doi.org/10.3390/jcm14238359
Editor's version
https://doi.org/10.3390/jcm14238359Type of document
Collections
La licencia de este ítem se describe como Attribution 4.0 International